Frontispiece: The Glycoproteomics–MS for Studying Glycosylation in Cardiac Hypertrophy and Heart Failure | Zendy

Yang Shuang | Zendy; Chatterjee Subroto | Zendy; Cipollo John | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Frontispiece: The Glycoproteomics–MS for Studying Glycosylation in Cardiac Hypertrophy and Heart Failure

Author(s) -

Yang Shuang,

Chatterjee Subroto,

Cipollo John

Publication year - 2018

Publication title -

proteomics – clinical applications

Language(s) - English

Resource type - Reports

SCImago Journal Rank - 0.948

H-Index - 54

eISSN - 1862-8354

pISSN - 1862-8346

DOI - 10.1002/prca.201870042

Subject(s) - glycosylation , heart failure , biomarker , cardiology , medicine , glycoproteomics , muscle hypertrophy , cardiac hypertrophy , chatterjee , left ventricular hypertrophy , glycan , glycoprotein , chemistry , biochemistry , blood pressure , bengali , linguistics , philosophy

Aberrant protein glycosylation is associated with the occurrence of cardiac hypertrophy. Heart arterial blood contains a biomarker (brain naturetic protein: BNP) with normal glycosylation, but substantially upregulated when cardiac hypertrophy occurs. The BNP is decorated by O‐glycans. The cover design stands for (1) HCM heart diseases reviewed in the paper; (2) BNP is the gold standard biomarker for HCM; (3) BNP has a remarkable O‐glycosylation after HCM occurs; (4) Background shows the glycan biosynthesis. This is reported by Shuang Yang, Subroto Chatterjee, John Cipollo in article number 1700075 .

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research